- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03945396
Homeopathy for Overweight and Obesity in Mexican Adolescents
Efficacy of a Multidisciplinary Intervention and Homeopahy for Overweight or Obesity in Mexican Adolescents: a Study Protocol for a Randomized Double-blind, Placebo-controlled Trial
Study Overview
Status
Conditions
Detailed Description
Overweight and obesity in children and adolescents are a major public health issue in Mexico. Whilst many factors (genetic, cultural, socioeconomic and environmental) contribute to develop obesity during childhood, a multidisciplinary intervention (nutritional, behavioral and exercise) is the best approach to improve weight loss. In Mexico, the use of homeopathy for obesity is widespread. Although there are some homeopathic medicines used for obese individuals, there is a lack of well-designed clinical trials to demonstrate its efficacy in weight loss. Calcarea carbonica ostrearum is a homeopathic mineral medicine. Previously, it has been demonstrated that Calcarea carbonica has an effect in reducing the percentage of fat in adolescents.
Therefore, a randomized, placebo-controlled, double-blind, parallel, superiority trial with a 3 month study duration, will be conducted to prove the efficacy and safety of Calcarea carbonica ostrearum in reducing weight, body mass index (BMI) and fat percentage, as well as, to prove its effect on the lipid profile, fasting serum glucose, glycosylated hemoglobin and insulin.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 07760
- Hospital Juarez de Mexico
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 12 to 19 years old.
- At least elementary school.
- Overweight (BMI ≥ 85th but <95th percentile based on the Centers for Disease Control and Prevention growth chart) or obese (BMI ≥95th percentile).
- Fasting serum glucose <126 mg/dl.
- Glycosylated hemoglobin <6.5%.
- With symptoms that match with Calcarea carbonica ostrearum.
- Willingness to participate, and verbal and written consent.
Exclusion Criteria:
- Pregnancy or breastfeeding.
- Cases already undergoing treatment (homeopathic, nutritional or structured physical activity) for obesity within last three months.
- Currently use of metformin, orlistat, insulin, other antidiabetic medication, contraceptive pills, medications with effects on lipid metabolism [thiazide and loop diuretics, β and α receptor blockers, antiepileptic drugs (carbamazepine, phenytoin, valproic acid, phenobarbital), antipsychotics (clozapine), protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), tamoxifen, raloxifene, isotretinoin, acitretin, ciclosporin, azathioprine, sirolimus].
- Any condition that prevents physical exercise.
- Diabetes, hypertension, thyroid diseases, Down syndrome, mental retardation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Multidisciplinary intervention + homeopathic medication
Multidisciplinary intervention (diet, exercise program, motivational support) and Calcarea carbonica ostrearum 30c. A single dose of Calcarea carbonica ostrearum 30C dissolved in a 30 ml bottle of 30% alcohol-distilled water. Patients will receive 8 drops PO three times per day prior agitation. |
A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
Other Names:
Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down. Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day. Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight.
Other Names:
|
Active Comparator: Multidisciplinary intervention + homeopathic placebo
Multidisciplinary intervention (diet, exercise program, motivational support) and placebo. Placebo will be prepared with 30% alcohol-distilled water only, in the same 30 ml bottle. Patients will receive 8 drops PO three times per day prior agitation. |
Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down. Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day. Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight.
Other Names:
A 30 ml bottle of 30% alcohol-distilled water.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in mean total weight in kilograms (kg)
Time Frame: At baseline and week 4, 8 and 12.
|
Weight measured with the participants barefooted and lightly dressed, with a Tanita scale Fitscan BC-545 F segmental body composition monitor.
The scale has an eight electrode body composition monitor that displays twenty readings; ten whole body and ten segmental (arms, legs and trunk area).
|
At baseline and week 4, 8 and 12.
|
Change from baseline in percentage of body fat
Time Frame: At baseline and week 4, 8 and 12.
|
Body fat measured with Tanita scale Fitscan BC-545 F segmental body composition monitor.
Values greater than 30% for females, and 25% for males, are considered high and of risk
|
At baseline and week 4, 8 and 12.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in mean total body mass index (BMI).
Time Frame: At baseline and week 4, 8 and 12.
|
Weight/height2 (kg/m2).
Overweight (BMI ≥ 85th but <95th percentile based on the Centers for Disease Control and Prevention growth chart) or obese (BMI ≥95th percentile).
|
At baseline and week 4, 8 and 12.
|
Change from baseline in mean total fat mass index
Time Frame: At baseline and week 4, 8 and 12.
|
Calculated by dividing fat weight in kilograms by height in meters squared.
|
At baseline and week 4, 8 and 12.
|
Change from baseline in mean total lean body mass (kg).
Time Frame: At baseline and week 4, 8 and 12.
|
Calculated by subtracting body fat weight from total body weight: total body weight is lean plus fat
|
At baseline and week 4, 8 and 12.
|
Change from baseline waist-hip ratio.
Time Frame: At baseline and week 4, 8 and 12.
|
Calculated as waist measurement divided by hip measurement.
|
At baseline and week 4, 8 and 12.
|
Change from baseline in mean total lean muscle mass (kg).
Time Frame: At baseline and week 4, 8 and 12.
|
Calculated by total weight of the body minus all the weight due to the fat mass.
|
At baseline and week 4, 8 and 12.
|
Number and severity of all adverse events
Time Frame: After participants consent and enrolled in the study and 15 days after study completion.
|
Adverse event will be defined as any untoward medical occurrence in a subject without regard to the possibility of a causal relationship.
|
After participants consent and enrolled in the study and 15 days after study completion.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in mean total fasting serum glucose (mg/dL)
Time Frame: At baseline and week 12.
|
Blood samples will be collected by venipuncture in the antecubital region of patients after 10-12 hours of overnight fasting and centrifuged within 30-45 min of collection, using an automated chemical analyzer (Advia®1200).
Glucose will be assayed by the glucose-oxidase method.
|
At baseline and week 12.
|
Change from baseline in mean total fasting serum triglycerides (mg/dL)
Time Frame: At baseline and week 12.
|
Blood samples will be collected by venipuncture in the antecubital region of patients after 10-12 hours of overnight fasting and centrifuged within 30-45 min of collection, using an automated chemical analyzer (Advia®1200).
|
At baseline and week 12.
|
Change from baseline in mean total cholesterol (mg/dL)
Time Frame: At baseline and week 12.
|
Blood samples will be collected by venipuncture in the antecubital region of patients after 10-12 hours of overnight fasting and centrifuged within 30-45 min of collection, using an automated chemical analyzer (Advia®1200).
|
At baseline and week 12.
|
Change from baseline in mean total high-density cholesterol (mg/dL)
Time Frame: At baseline and week 12.
|
Blood samples will be collected by venipuncture in the antecubital region of patients after 10-12 hours of overnight fasting and centrifuged within 30-45 min of collection, using an automated chemical analyzer (Advia®1200).
|
At baseline and week 12.
|
Change from baseline in mean total low-density cholesterol (mg/dL)
Time Frame: At baseline and week 12.
|
Blood samples will be collected by venipuncture in the antecubital region of patients after 10-12 hours of overnight fasting and centrifuged within 30-45 min of collection, using an automated chemical analyzer (Advia®1200).
|
At baseline and week 12.
|
Change from baseline in percentage of glycosylated hemoglobin
Time Frame: At baseline and week 12.
|
Blood samples will be collected by venipuncture in the antecubital region of patients after 10-12 hours of overnight fasting and centrifuged within 30-45 min of collection, using an automated chemical analyzer (Advia®1200).
|
At baseline and week 12.
|
Change from baseline in mean total insulin (mU/ml)
Time Frame: At baseline and week 12.
|
Blood samples will be collected by venipuncture in the antecubital region of patients after 10-12 hours of overnight fasting and centrifuged within 30-45 min of collection, using a chemiluminescence technique (Immulite®2000TSH Third Generation).
|
At baseline and week 12.
|
Change from baseline in mean total thyroid-stimulating hormone (mU/L)
Time Frame: At baseline and week 12.
|
Blood samples will be collected by venipuncture in the antecubital region of patients after 10-12 hours of overnight fasting and centrifuged within 30-45 min of collection, using a chemiluminescence technique (Immulite®2000TSH Third Generation).
|
At baseline and week 12.
|
Change from baseline in mean total HOMA-IR.
Time Frame: At baseline and week 12.
|
The homeostasis model assessment (HOMA), an epidemiologic method for assessing insulin resistance [HOMA-IR=insulin (mU/ml) X glucose (mg/dl)/405] will be used as surrogate measure of insulin sensitivity
|
At baseline and week 12.
|
Change from baseline in mean total score of CES-D-R
Time Frame: At baseline and week 12.
|
CESDR scale measure symptoms of depression in nine different groups as defined by the American Psychiatric Association Diagnostic and Statistical Manual, fifth edition.
The Total CESD-R Score is calculated as a sum of responses to all 20 questions.
The range of possible scores is between 0 (for those who say 'not at all or less than one day to all 20 questions' and 60 (for those who say '5-7 days' or 'nearly every day for 2 weeks' for all 20 questions).
No clinical significance: a total CESD-R score less than 16 across all 20 questions.
|
At baseline and week 12.
|
Change from baseline in mean total score of Screen for Child Anxiety Related Emotional Disorders (SCARED).
Time Frame: At baseline and week 12.
|
Appropriate screening tool to aid the diagnosis of anxiety disorders in adolescents attending an outpatient clinic.It consists of 41 items that are rated from 0 to 2, being 0 never, 1 sometimes and 2 always.
The cut-off point is 25, that is, there is a probability of at least 70% that the child or adolescent has an anxiety disorder.
|
At baseline and week 12.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HJM 0572/19-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
-
University of British ColumbiaTerminatedOverweight and ObesityCanada
-
National Taiwan University HospitalCompleted
Clinical Trials on Homeopathic Medication
-
Southwest College of Naturopathic MedicineSamueli Institute for Information BiologyCompleted
-
Shaare Zedek Medical CenterUnknownPatients Undergoing Open Heart Surgery | Patients Undergoing Lung SurgeryIsrael
-
Michael FrassSigmund Freud PrivatUniversitatCompletedAdjustment Reaction With Physical SymptomsAustria
-
Shaare Zedek Medical CenterCompleted
-
Federal University of São PauloCompleted
-
Medical University of ViennaCompleted
-
Charite University, Berlin, GermanyTerminatedMajor DepressionGermany
-
University of TorontoCentre for Addiction and Mental Health; Lotte & John Hecht Memorial FoundationActive, not recruitingAttention Deficit Hyperactivity DisorderCanada
-
Integrative Medicine InstituteSouthwest College of Naturopathic Medicine; Heel GmbHWithdrawn
-
Medical University of ViennaCompleted